Phase 2 trial of treatment for contact lens discomfort reaches primary endpoints
Click Here to Manage Email Alerts
AZR-MD-001, under investigation for the treatment of contact lens discomfort, has reached the primary endpoints in the phase 2 ECLIPTIC study, according to a press release from Azura Ophthalmics.
Topline results from the single-center, single-masked, vehicle-controlled, randomized, parallel-group study showed 26 participants treated with twice-weekly AZR-MD-001 (selenium disulfide), applied to the lower lid margin, had significantly improved meibum gland secretion scores after 14 days (mean score improvement, 3.4; P < .05), with improvement continuing until the end of the study (mean score improvement, 14.3; P < .0001). The vehicle-treated group had no significant differences in meibum gland secretion scores.
By 1 month, subjects treated with AZR-MD-001 experienced significant improvements in contact lens comfort.
“We are excited by the results of the ECLIPTIC study, which validate the potential of our dermatological approach and suggest that ophthalmic keratolytics could be an effective treatment option for the millions of patients who experience contact lens discomfort,” Marc Gleeson, CEO of Azura, said in the release.
Read more about
Click Here to Manage Email Alerts